{"id":"W3217353697","doi":"10.1016/s2352-3026(21)00311-2","title":"Polatuzumab vedotin plus obinutuzumab and lenalidomide in patients with relapsed or refractory follicular lymphoma: a cohort of a multicentre, single-arm, phase 1b/2 study","year":2021,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":false,"ca_institutions":"Roche (Canada)","funders":"Genentech; Roche","keywords":"Lenalidomide; Medicine; Follicular lymphoma; Obinutuzumab; Internal medicine; Rituximab; Oncology; Lymphoma; Cohort; Neutropenia; Tolerability; Brentuximab vedotin; Gastroenterology; Chemotherapy; Adverse effect; Multiple myeloma; CD30","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002651066,0.001208908,0.002460734,0.0003292123,0.0005400268,0.002024393,0.0007956461,0.001084241,0.00151066],"category_scores_gemma":[0.002490144,0.00062659,0.002205645,0.0006920974,0.0008926645,0.001336528,0.0004940995,0.002260243,0.0004630085],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001300431,"about_ca_system_score_gemma":0.001221287,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001655482,"about_ca_topic_score_gemma":0.002470385,"domain_scores_codex":[0.9984605,0.0007076357,0.00009020208,0.000308164,0.000141666,0.0002917733],"domain_scores_gemma":[0.9986014,0.000302519,0.0003101183,0.0002179403,0.0001122043,0.00045584],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8225631,0.009662134,0.08779611,0.0005917973,0.01028099,0.0004356857,0.0005118678,0.00127902,0.01222686,0.0002382224,0.00289818,0.051516],"study_design_scores_gemma":[0.5016083,0.1997957,0.2769915,0.0001276389,0.009784328,0.001014356,0.0005372345,0.001326671,0.001810115,0.0006149332,0.006237526,0.0001517341],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9963271,0.002108525,0.000111751,0.0001554129,0.00005935818,0.0002281964,0.0004746596,0.00001221969,0.0005228823],"genre_scores_gemma":[0.9963592,0.0007951003,0.0002439389,0.0004121342,0.0001213988,0.0002423875,0.001212779,0.00001269484,0.0006004603],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002651066,"threshold_uncertainty_score":0.01402032,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02440419732320716,"score_gpt":0.2849671350911839,"score_spread":0.2605629377679768,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}